Product Description
For Major Depressive Disorder and/or Post-traumatic Stress Disorder (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05117632)
Mechanisms of Action: BDNF
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alto Neuroscience
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Bipolar Disorder|Depressive Disorder, Major
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06656416 |
BD-D | P2 |
Recruiting |
Bipolar Disorder|Depressive Disorder, Major |
2026-08-01 |
12% |
2025-07-17 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT05712187 |
ALTO-100-201 | P2 |
Completed |
Depressive Disorder, Major |
2024-09-05 |
50% |
2025-07-17 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05419869 |
ALTO-100-003 | P2 |
Completed |
Depressive Disorder, Major |
2023-01-13 |
71% |
2023-02-10 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |